Anticoagulation via anti-Factor Xa inhibition

Lupus

Volumn 15, Issue 3, 2006, Pages 167-171

  Wiles, N ^a   Hunt, Beverley J ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation; Factor Xa inhibition; Fondaparinux; Thromboprophylaxis

Indexed keywords

ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; ANTICOAGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBIN III; CORONARY DISEASE; HUMANS; POLYSACCHARIDES; THROMBOSIS; VENOUS THROMBOSIS;

EID: 33645994484     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2275rr     Document Type: Conference Paper

References (28)

1. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126 (3 Suppl): 338S-400S.
2. Rashid ST, Thursz MR, Razvi NA et al. Venous thromboprophylaxis in medical patients. Journal of the Royal Society of Medicine 2005; 98: 507-512.
3. Alban S. From heparins to factor Xa inhibitors and beyond. European Journal of Clinical Investigation 2005; 35 (Suppl 1): 12-20.
4. Ranze O, Eichner A, Lubenow N, Kempf R, Greinacher A. The use of low-molecular-weight heparins in heparin-induced thrombocytopenia (HIT): a cohort study. Annals of Haematology 2000; 79: 198-199.
5. Warkentin TE. Heparin induced thrombocytopenia: pathogenesis and management. British Journal of Haematology 2003; 121: 535-555.
6. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-407.
7. Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. The New England Journal of Medicine 2001; 344: 619-625.
8. Donat F, Duret JP, Santoni A et al. The pharmacokinetics of fondaparinux in healthy volunteers. Clinical Pharmakokinetics 2002; 41 (Suppl 2): 1-9.
9. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thrombosis and Haemostasis 1995; 74: 1474-1477.
10. Amiral J, Lormeau JC, Marfaing-Koka A et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagulation and Fibrinolysis 1997; 8: 114-117.
11. Turpie AGG, Bauer K, Eriksson IB, Michael RL. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery. Archives of Internal Medicine 2002; 162: 1833-1840.
12. Turpie AGG, Bauer K, Eriksson IB, Michael RL. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 2004; 126: 501-508.
13. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery - A multicenter, randomized, placebo-controlled, double-blind study. Archives of Internal Medicine 2003; 163: 1337-1342.
14. Agnelli G, Bergqvist D, Cohen A, Gallus AS, Gent MA. A randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux (Atrixa) and postoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS study. Blood 2003; 102: (abstract 40).
15. Cohen AT, Davidson BL, Gallus AS et al. Fondaparinux for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine 2003; 102: (abstract 42).
16. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated Heparin in the initial treatment of pulmonary embolism. The New England Journal of Medicine 2003; 349: 1695-1702.
17. The Matisse Investigators. Fondaparinux or Enoxaparin for the initial treatment of symptomatic deep vein thrombosis. Annals of Internal Medicine 2004; 140: 867-873.
18. Simoons ML, Bobbink IW, Boland J et al. A dose finding study of fondaparinux in patients with non-ST segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. Journal of the American College of Cardiology 2004; 43: 2183-2190.
19. Faaij RA, Burggraaf J, Schoemaker RC, van Amsterdam RGM, Cohen AF. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Journal of Clinical Pharmacology 2002; 54: 304-308.
20. Gosselin RC, King JH, Janatpur KA, Dager WH, Larkin EC, Owings JT. Effects of pentasaccharides (fondaparinux) and direct thrombin inhibitors on coagulation testing. Archives of Pathology and Laboratory Medicine 2004; 128: 1142-1145.
21. Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O. Effect of low molecular weight heparin (dalteparin) and fondaparinux on human osteoblasts in vitro. The British Journal of Surgery 2005; 92: 177-183.
22. Maetzke J, Hinrichs R, Schneider L, Scharffetter-Kochanek K. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux. Allergy 2005; 60: 413-415.
23. Hawkins D, Evans J. Minimising the risk of heparin induced osteoporosis during safety. Expert Opinion on Drug Safety 2005; 4: 583-590.
24. Dempfle D. Minor transplacental passage of fondaparinux in vivo. The New England Journal of Medicine 2004; 350: 1914-1915 (correspondence).
25. Paolucci F, Frasa H, Van Aarle, F et al. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Atrixa) in human plasma and other biological matrices. Clinical Laboratory 2003; 49: 451-460.
26. Gerotziafas-Grigoris T, Chakroun T, Samama M, Elalamy I. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thrombosis and Haemostasis 2004; 92: 1296-1302.
27. Huvers F, Slappendel R, Benraad B, van-Hellemont G, van-Kraaij-M. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. The Netherlands Journal of Medicine 2005; 63: 184-186.
28. Lisman T, Bijsterveld NR, Adelmeijer J et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. Journal of Thrombosis and Haemostasis 2003; 1: 2368-2373.